In the last 90 days, AtriCure, Inc. insiders filed 0 open-market purchases and 7 sales; 251 institutions reported holding it in 13F filings for Q2 2026, worth $1.47B in total; no superinvestor holds it.
SEC filings
10-K, 10-Q, 8-K, 20-F and 40-F reports AtriCure, Inc. filed with the SEC, newest first.
Livermore lists each filing's form, 8-K items and dates only. To read a filing, open it on SEC.gov; an 8-K's press release or other attachments, such as exhibit 99.1 for Item 2.02, are in the filing index.
5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.07Item 5.07: Results of a shareholder vote9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement2.02Item 2.02: Results of operations and financial condition (earnings release)2.03Item 2.03: New direct financial obligation, such as new debt or an off-balance-sheet obligation9.01Item 9.01: Financial statements and exhibits
5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.07Item 5.07: Results of a shareholder vote9.01Item 9.01: Financial statements and exhibits
5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year5.07Item 5.07: Results of a shareholder vote9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement1.02Item 1.02: Termination of a material definitive agreement2.02Item 2.02: Results of operations and financial condition (earnings release)2.03Item 2.03: New direct financial obligation, such as new debt or an off-balance-sheet obligation9.01Item 9.01: Financial statements and exhibits
5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.07Item 5.07: Results of a shareholder vote9.01Item 9.01: Financial statements and exhibits
